Medipal Holdings (7459) AI Stock Analysis

• Market Cap: $449.20B
• Dividend Yield: 2.55%
• Average Volume (3M): 406.85K
• Price to Earnings (P/E): 12.6
• Beta (1Y): 0.52
• Revenue Growth: 4.09%
• EPS Growth: 34.49%
• Country: JP
• Employees: 13,075
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Distribution
• EPS (TTM): 19.54
• Shares Outstanding: 219,226,040
• 10 Day Avg. Volume: 423,890
• 30 Day Avg. Volume: 406,850
• PEG Ratio: -0.68
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2,490.47
• Price Target Upside: 2.38% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 78 Outperform
• Price Target: ―

Medipal Holdings is fundamentally strong with a robust balance sheet and consistent profitability. Despite limited recent cash flow data, the company maintains a strong financial position. Technical indicators suggest potential downward pressure, but the low P/E ratio and solid dividend yield underscore its undervaluation, balancing the overall score.

Medipal Holdings Business Overview & Revenue Model

Company Description

Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; food processing raw materials for agriculture, fisheries, and livestock; and livestock feed additives, seasonings, veterinary medical equipment, packaging materials, industrial chemicals, and other products. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; health insurance claims reviews, medical coding dispatch, outsourcing, and remote education activities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; and planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand. Medipal Holdings Corporation serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Medipal Holdings makes money through its extensive distribution and wholesaling operations. The company's primary revenue streams include the sale and distribution of pharmaceuticals to hospitals, clinics, and pharmacies; the distribution of cosmetics and daily necessities to retailers; and the provision of animal health products. Medipal leverages its strong logistics infrastructure to deliver products efficiently, thereby maintaining significant market share in Japan. Strategic partnerships with pharmaceutical manufacturers and healthcare providers also play a crucial role in its revenue generation, ensuring a steady supply of products and access to the latest medical innovations.

Medipal Holdings Financial Statement Overview

Summary

Medipal Holdings demonstrates strong financial health with a consistent revenue and profit growth, a robust balance sheet with no debt, and historically effective cash flow management. Limitations in recent cash flow data slightly impact the overall financial assessment.

Income Statement

Medipal Holdings demonstrates strong profitability with a consistent gross profit margin around 6.8% and a net profit margin improving to 1.35% in TTM. Revenue growth is positive with a 7.24% increase from the previous annual report. The EBIT and EBITDA margins have shown resilience, indicating operational efficiency.

Balance Sheet

The company's balance sheet is robust with zero total debt, resulting in a debt-to-equity ratio of 0, which is favorable. The equity ratio stands at 32% in TTM, reflecting a solid equity base. The return on equity is strong at 7.9% in TTM, highlighting effective management of equity capital.

Cash Flow

While the operating cash flow is not available for TTM, the company had a substantial free cash flow in the previous period. Historically, operating cash flow to net income ratios have been healthy, but the absence of TTM data limits the assessment. Overall, cash flows have been managed effectively in prior periods.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.67T	3.56T	3.36T	3.29T	3.21T
Gross Profit	242.25B	246.66B	224.31B	217.44B	214.26B
EBITDA	95.16B	92.73B	63.62B	71.64B	64.08B
Net Income	40.28B	41.47B	38.81B	29.42B	23.93B
Balance Sheet
Total Assets	1.82T	1.80T	1.70T	1.71T	1.68T
Cash, Cash Equivalents and Short-Term Investments	261.41B	230.47B	195.03B	261.92B	241.52B
Total Debt	0.00	0.00	7.38B	30.08B	30.58B
Total Liabilities	1.07T	1.06T	1.02T	1.06T	1.04T
Stockholders Equity	619.57B	600.35B	561.36B	530.30B	523.01B
Cash Flow
Free Cash Flow	51.70B	42.45B	2.64B	42.34B	18.78B
Operating Cash Flow	60.56B	61.84B	16.15B	61.22B	34.45B
Investing Cash Flow	-3.36B	-7.82B	-39.49B	-24.34B	-2.94B
Financing Cash Flow	-25.95B	-25.25B	-43.54B	-16.47B	-16.00B

Medipal Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2432.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Positive. The current price of 2432.5 is above the 20-day moving average (MA) of 2361.85, above the 50-day MA of 2330.23, and above the 200-day MA of 2349.28, indicating a bullish trend. The MACD of 26.01 indicates Negative momentum. The RSI at 66.55 is Neutral, neither overbought nor oversold. The STOCH value of 90.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7459.

Medipal Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7459	78 Outperform	$449.20B	12.59	6.53%	2.55%	4.09%	34.49%
Sector *	58 Neutral	£4.74B	6.56	-62.36%	102.23%	34.03%	6.31%
ARHCF	―	$2.71B	14.65	5.65%	0.47%	―	―
SZUKF	―	$2.11B	12.43	8.32%	1.83%	―	―
3151	70 Outperform	¥55.48B	8.27		3.65%	2.19%	30.09%
3349	70 Neutral	¥734.15B	23.60		0.70%	6.96%	18.31%
8129	69 Neutral	¥313.22B	15.32		1.36%	2.83%	-2.76%

Medipal Holdings Corporate Events

Medipal Holdings Increases Year-End Dividend Forecast

Medipal Holdings Corporation announced a revision to its year-end dividend forecast, increasing it to ¥32 per share, up by ¥2 from the previous forecast. This decision aligns with the company’s strategy to enhance shareholder returns and achieve a total shareholder return ratio of 40% over a five-year period, reflecting its commitment to financial soundness and capital efficiency.

MEDIPAL Announces Merger of Subsidiaries to Boost Medical Sales

MEDIPAL HOLDINGS CORPORATION has announced the conclusion of an absorption-type merger agreement between its wholly owned subsidiaries, ATOL CO., LTD and MVC CO., LTD. This strategic move aims to leverage the strengths of both companies to enhance the sales channels and development of medical equipment sales in the Kyushu and Okinawa areas. Since the merger involves wholly owned subsidiaries, it will not impact the consolidated financial results for the current fiscal year.

Medipal Holdings Reports Strong Q3 2025 Financial Results with Strategic Expansions

Medipal Holdings Corporation reported a notable financial performance for the third quarter of the fiscal year ending March 31, 2025, with net sales reaching ¥2,807,172 million, marking a 3.4% increase from the previous year. The company’s operating profit surged by 21.9%, driven by strategic consolidations including the integration of PreMedica Inc., FloraDiscovery Inc., and PRESUSCUBE Corporation, enhancing its market positioning and operational scope.